Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: JACC: CardioOncology Controversies in Cardio-Oncology

JACC CardioOncol. 2024 Apr 16;6(2):322-324. doi: 10.1016/j.jaccao.2024.02.004. eCollection 2024 Apr.

Jenica N Upshaw^{1

2}, Susan K Parson^{2

3}, Rachel J Buchsbaum³, Ilana Schlam³, Kathryn J Ruddy⁴, Urshila Durani⁵, Narendranath Epperla⁶, Darryl P Leong⁷

¹ Division of Cardiology, Tufts Medical Center, Boston, Massachusetts, USA.
² Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
³ Division of Hematology-Oncology, Tufts Medical Center, Boston, Massachusetts, USA.
⁴ Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
⁵ Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
⁶ Division of Hematology, Ohio State University, Columbus, Ohio, USA.
⁷ Department of Medicine and the Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

No abstract available

Keywords: anthracycline; cancer; cancer survivorship; cardiomyopathy; cardioprotection; heart failure.

Publication types